Kornimate/medical-research-clean huggingface dataset:
minimally invasive ridge augmentation

Conditions: Alveolar Bone Loss; Bone Density Increased

Summary: the present study is a human, prospective, randomised controlled clinical trial conducted to explore the outcome of a minimally invasive ridge augmentation technique with and without low level laser therapy. the trial is in accordance with the consolidated standards of reporting trials (consort) criteria, 2010.

twenty healthy individuals satisfying the inclusion and exclusion criteria were recruited for the study. a detailed, thorough medical and dental history was obtained and each patient was subjected to comprehensive clinical and radiological examination. all patients were informed about the nature of the study, the surgical procedure involved, potential benefits and risks associated with the surgical procedure and written informed consent were obtained from all patients. all the patients were treated with subperiosteal minimally invasive aesthetic ridge augmentation technique. the test group of ten were given low level laser therapy as an adjunct. the clinical and radiographic parameters were recorded at baseline and six months postoperatively.

Eligibility criteria:
inclusion criteria: * single or multiple edentulous sites with seibert's class 1 defects corresponding to colognes 1 and 2 * asa 1 and 2 * patients with an esthetic concern * good oral hygiene exclusion criteria: * seibert's class 2 defects * asa 3 and 4 * osteoporosis * uncontrolled diabetes * immunosuppression * radiation therapy and bisphosphonate therapy * gingival thickness less than 2 mm
venous: a translational study of enterococcal bacteremia

Conditions: Enterococcal Bacteremia

Summary: the purpose of this study is to assemble a multicenter prospective cohort of patients with enterococcal bloodstream infections (bsis) to provide data on outcomes of patients with enterococcal bsis for sample size calculations for future trials, as well as to characterize enterococcal isolates causing bsis in order to comprehensively dissect the molecular epidemiology of infecting organisms for future studies.


Eligibility criteria:
inclusion criteria: * hospitalized patient * ≥1 positive blood culture with enterococcus spp. (vre or vse) during hospitalization * bacterial isolate(s) is/are available for further characterization * repeat blood culture(s) within 7 days from the first positive culture exclusion criteria: * cultures obtained from patients not admitted to the hospital * isolate(s) not available for further studies.

Keywords: entercoccal bloodstream infection vancomycin-resistant enterococci vancomycin-susceptible enterococci
extracorporeal cardiac shock wave therapy (cswt) for treatment of coronary artery disease

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to determine the effectiveness of cardiac shock wave therapy (cswt) for the treatment of severe coronary artery disease (cad) in a chinese cohort.

this study was approved by the institutional review board and ethics committee of 1st hospital of kunming medical university, and all study subjects signed informed consent for participation in the study and all treatments performed. subjects were patients who were hospitalized at department of cardiology of our hospital from december 2008 to december 2009. patients were eligible to be included in the study if they met any of the following criteria: 1) coronary angiography (ca) or multi-slice ct coronary angiography (ctca) suggestive of moderate to severe coronary artery stenosis. 2) chest tightness, onset of shortness of breath, and poor exercise tolerance after receiving formal drug treatment (with or without stent or bypass graft). 3) hospitalized more than 2 times within 1 year due to the aforementioned problems. 4) ccs angina grading higher than grade ii, and nyha functional classification of i-iii. 5) more than 1 month after acute myocardial infarction (ami) and more than 2 weeks after pci surgery. the diagnosis and treatment in all the patients was in accordance with the related domestic and european guidelines developed in 2007

Eligibility criteria:
inclusion criteria: * coronary angiography or multi-slice spiral ct coronary angiography suggestive of moderate to severe coronary artery stenosis. * chest tightness, onset of shortness of breath, and poor exercise tolerance after receiving formal drug treatment with or without stent or bypass graft). * hospitalized more than 2 times within 1 year due to the aforementioned problems. * canadian cardiovascular society angina grading higher than grade ii, and new york heart association functional classification of i-iii. * more than 1 month after acute myocardial infarction (ami) and more than 2 weeks after pci surgery. the diagnosis and treatment in all the patients was in accordance with the related domestic and european guidelines developed in 2007. exclusion criteria: * acute myocardial infarction or coronary artery bypass graft within the 4 weeks prior to the study. * history of heart transplantation. * history of metal valve replacement surgery. * intracardiac thrombus. * left ventricular ejection fraction \< 30% and unstable hemodynamics. * arrhythmia with a rate \ 120 bpm. * skin ulceration or infection in the treatment area. * severe obstructive lung disease.

Keywords: coronary artery disease angina pectoris myocardial ischemia cardiac shock wave therapy
reducing adolescent pregnancy

Conditions: Pregnancy in Adolescence; Counseling; Contraception Behavior

Summary: this multi-site study is employing a brief contraception counseling intervention in the emergency department (ed) to shed light on factors that affect decision making as well as barriers and facilitators to conception initiation in the emergency department (ed) setting. the overarching goal of the study is to reduce unintended pregnancy among females ages 15 to 18 who present to the emergency department (ed).

this study is a prospective cohort study involving females who present to one of two emergency departments (ed) between the ages of 16 and 18, who are at risk of unintended pregnancy. our primary objective is to assess intention to initiate contraception ("high"=very/somewhat likely vs "low"=unsure/not likely/definitely not on likert scale survey) among females aged 15 to 18 years who receive emergency department-based contraceptive counseling. our secondary objectives are as follows: 1. among the same population, assess completion of a referral for any contraceptive care, defined as attendance at a referral site within 4 weeks after the index ed visit. 2. assess the proportion who ultimately initiate contraception through electronic medical record documentation (i.e., visit note, procedure note, medication review) and participant report (follow-up calls). 3. use qualitative interview methodology to explore attitudes, barriers, and facilitators that affect decisions to a) express intention to initiate contraception, b) complete a referral for contraceptive care, and c) ultimately initiate contraception among this unique group of high-risk adolescents.

Eligibility criteria:
inclusion criteria: 1. females aged 15-18 years who are at high-risk of pregnancy, defined as sexual activity within the last 6 months or likely future sexual activity. 2. females who do not desire to become pregnant within the next year. 3. eligible individuals must be proficient in speaking and reading in english. 4. consent of the adolescent. exclusion criteria: 1. females who are currently using hormonal contraception or an intrauterine device. 2. females who are pregnant. 3. patient has a developmental delay limiting participation. 4. patient is presenting in the ed after sexual assault. 5. patient is too ill to be screened. apps: \[no age limit\]\] have been working in ed 6 months

Keywords: contraception counseling adolescent pregnancy contraception initiation
surveillance for adverse events following influenza immunization

Conditions: Influenza; Vaccines Adverse Reaction

Summary: influenza vaccines are continuously modified to adjust to the virus antigenic shifts or drifts, and its safety profile may vary. while generally considered safe, influenza vaccines have been associated in the past with increases in cases of guillain-barré syndrome (1976) and with oculorespiratory syndrome in 2001. last year, with the vaccination against the ph1n1, an increase of allergic-like reactions was observed. passive surveillance is collecting notifications of adverse events (ae) on the whole population but the sensitivity of this system is not high and its timeliness is not necessarily optimal. last year, with the new pandemic influenza vaccine the investigators piloted a web-based active surveillance of a large number of health care workers (hcw) vaccinated with the new adjuvanted monovalent ph1n1 influenza vaccine (arepanrix® gsk, canada). because healthcare workers (hcw) constituted a well-defined group with general good health and received the influenza vaccine in priority, this group of people was well suited for monitoring the safety of the influenza vaccine. for this study, 6242 hcw were recruited in three different sites (5183 were from quebec). a total of 468 events (local reactions, fever, systemic reactions, gastrointestinal and respiratory problems) were reported by 430 hcw. 80% of the hcw recruited completed at least one of the three surveys and 52% responded to all questionnaires. during this surveillance, the investigators didn't have unexpected findings but this active surveillance of adverse events among healthcare workers would have been effective enough to rapidly detect adverse events occurring at a rate ≥ 1 per 200 vaccinees. for this year the investigators want to expand the surveillance to more sites and more participants to be able to detect ae occurring at rates ≥ 1 per 500 vaccinees, and to increase the response rate to all three surveys in participants. the main objective of this project is to estimate in hcw vaccinated against influenza the frequency of adverse events of sufficient severity to cause work absenteeism or medical consultation. this year the network will include 5 canadian hospitals (quebec city, vancouver, toronto, halifax, + another one ) with a total enrollment of \>10 000 hcw. this should allow us to detect ae occurring at a rate of ≥ 1 per 500 vaccinees.


Eligibility criteria:
inclusion criteria: * to be a healthcare worker from one of the seven canadian hospitals participating in the public health agency of canada/canadian institutes for health research-influenza research network (pcirn): quebec city, toronto, halifax, vancouver, ottawa and sherbrooke. * to have been immunized with the influenza vaccine 2010 * to have an email address * to be 18 years old and older * to have sign the consent form exclusion criteria: * pregnant women

Keywords: influenza vaccine safety adverse events health care workers
a study of ly900027 given by insulin pump to participants with type 1 diabetes mellitus

Conditions: Diabetes Mellitus, Type 1

Summary: the main purpose of this study is to learn more about a new formulation of insulin lispro when given by an insulin pump to participants with type 1 diabetes mellitus. the study will investigate how the body processes the drug and how the drug affects the body. information about side effects will be collected. the study will last from six to 12 weeks for each participant.


Eligibility criteria:
inclusion criteria: * diagnosis of t1dm for at least 1 year * fasting c-peptide ≤0.30 nanomoles per liter (nmol/l) * bbody mass index between 18.5 and 33.0 kilograms per square meter (kg/m²) * participants should have a glycated hemoglobin of ≤9.0% at screening exclusion criteria:
ursodiol on insulin sensitivity, gastric emptying and body weight with type 2 diabetes on metformin

Conditions: Type 2 Diabetes Mellitus

Summary: this study will evaluate whether bile acids are able to increase insulin sensitivity and enhance glycemic control in t2dm patients, as well as exploring the mechanisms that enhance glycemic control. these observations will provide the preliminary data for proposing future therapeutic as well as further mechanistic studies of the role of bile acids in the control of glycemia in t2dm.

background: intra-jejunal administration of bile acids improves insulin sensitivity. hypothesis: the bile acid, ursodeoxycholic acid (udca) in delayed (ileocolonic)-release formulation, stimulates bile acid membrane receptor (tgr-5) and farnesol x (fxr) receptors in the ileum and colon, increasing the secretion of fibroblast growth factor 19 (fgf-19), glp-1, oxyntomodulin (oxm), and peptide (pyy3-36), improving insulin sensitivity and inducing weight loss. aim: to study the effect of an ileocolonic formulation of udca on insulin sensitivity, postprandial plasma glycemia and incretin levels, gastric emptying and body weight in overweight or obese type 2 diabetic subjects on monotherapy with metformin. study design: this is a single center, placebo-controlled, parallel group, single dose randomized controlled trial to study the effect of delayed (ileocolonic)-release udca 600 mg twice daily on insulin sensitivity, gastric emptying of liquids and solids (measured by scintigraphy)and weight loss in overweight or obese type 2 diabetic subjects. participants will be receiving monotherapy with metformin. blood samples will be collected at defined times to measure glycemia and the incretin (glp-1, oxm, pyy3-36) fasting levels and responses to the meal. anticipated results: in comparison with placebo, udca will increase insulin sensitivity, enhance glycemic control, increase postprandial incretins, and delay gastric emptying (ge) of liquids. significance: this study will prove that ileocolonic-release udca enhances glycemic control in t2dm patients.

Eligibility criteria:
overweight or obese subjects with bmi\> 25 kg/m2 with type 2 diabetes mellitus on metformin, receiving standard of care for type 2 dm. otherwise individuals who are not currently on treatment for cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, neurological, endocrine (other than t2dm) and unstable psychiatric disease. men or women. women of childbearing potential will have a negative pregnancy test before initiation of medication.
investigation of the effect of steady state filibuvir on the pharmacokinetics of oral contraceptives (levonorgestrel and ethinyl estradiol)

Conditions: Hepatitis C

Summary: the purpose of this study is to estimate the effect of filibuvir on the pharmacokinetics of ethinyloestradiol \[ee\] and levonorgestrel \[ln\], to assess the safety and tolerability of 600 mg bid of filibuvir in healthy women and to investigate the pharmacokinetics of 600 mg bid of filibuvir in healthy women.

to investigate the effects of multiple oral doses of filibuvir on the steady state pharmacokinetics of oral contraceptive steroids in healthy female subjects.

Eligibility criteria:
inclusion criteria: * healthy female subjects between the ages of 18 and 45 years, inclusive (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ecg and clinical laboratory tests). * subjects must have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to period 1. * body mass index (bmi) of approximately 17.5 to 30.5 kg/m2; and a total body weight \>45 kg. * evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial. * willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures. * must be willing to practice an alternative method of contraception for the duration of the study in addition to oral contraceptive use. exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * any medical reason which would contraindicate the administration of oral contraceptives (as per label). including but not limited to history of unexplained vaginal bleeding, current breast cancer, active liver disease, uncontrolled hypertension, history of diabetes with vascular complications, history of venous thrombosis, stroke, ischemic heart disease, history of severe headaches with focal neurologic symptoms. * female subjects of non-childbearing potential who meet the following criteria: * post menopausal, aged between 45-55 who have been amenorrheic for \>2 years and who meet the criteria for serum fsh levels (\>30 iu/l), or * females who have undergone a hysterectomy, or * females who have undergone tubal ligation, or * females who have undergone bilateral oophorectomy. * history of discontinued use of oral contraceptives for medical reasons. * history of febrile illness within 5 days prior to the first dose. * any condition possibly affecting drug absorption (eg, gastrectomy).
treatment of severe covid-19 patients using secretome of hypoxia-mesenchymal stem cells in indonesia

Conditions: Covid-19; Cytokine Storm

Summary: in this randomized controlled trial (rct), severe cases of covid-19 infection will be treated with secretome of hypoxia-mesenchymal stem cells. the improvement in clinical, laboratory, and radiological manifestations will be evaluated in treated patients compared with the control group.

the devastating effect of severe acute respiratory syndrome coronavirus-2 (sars cov-2) infection is caused by a robust cytokine storm that leads to lung tissue damage. several studies reported a correlation between disease severity and the release of excessive proinflammatory cytokines, such as tumor necrosis factor-α (tnf-α), il-6, il-1, ifn-υ, ifn-υ-induced protein 10 (ip10), monocyte chemoattractant protein-1 (mcp-1), macrophage inflammatory protein-1a (mip-1a), and granulocyte-colony stimulating factor (g-csf). this finding was confirmed by the high level of plasma cytokines found in most severe covid-19 patients associated with extensive lung damage. therefore, finding an effective therapeutic option to control the devastating cytokine storm of covid-19 and regenerate the damaged lung is crucial. previous studies reported that the hypoxic condition of mscs could enhance the release of their active soluble molecules known as secretome-mscs (s-mscs), such as il-10 and tgf-β that useful in alleviating inflammation. moreover, they could also increase the expression of growth factors such as vegf and pdgf that accelerate lung injury improvement. these active molecules could potentially serve as a biological therapeutic agent for treating the severe sars-cov-2 infection. according to recent studies, we successfully isolated the s-mscs from their culture medium using tangential flow filtration (tff) strategy with several molecular weight cut-off category. this study investigated the clinical outcomes of severe covid-19 patients with several comorbidities treated with s-mscs in indonesia.

Eligibility criteria:
inclusion criteria: 1. patients whose clinical and laboratory test results have a positive diagnosis of covid-19. 2. patients who are willing to participate as subjects in the study by signing the informed content. 3. criteria for berlin to enter ards (moderate and severe) with or without a ventilator: * pao2 / fio2: moderate 100-200 * pao2 / fio2: severe \<100 4. one or more comorbid history 5. sofa score exclusion criteria: 1. the covid19 patient has fibrosis (based on the results of the chest x-ray or ct chest) 2. ecog 4 performance status, decreased irreversible consciousness, brain stem death. 3. severe nyha iii / iv heart failure 4. pregnant women

Keywords: secretome mesenchymal stem cells covid-19 hypoxia
carotid stenting in patients with high risk carotid stenosis ("soft plaque")

Conditions: Carotid Stenosis

Summary: stenting is an alternative to traditional surgery in the treatment of carotid stenosis.the intra and/or postprocedural cerebral embolization remains the most frequent complication. thanks to the systematic use of cerebral protection systems, these complications have reduced.a debate concerning which cerebral protective device should be more effective is still ongoing.


Eligibility criteria:
inclusion criteria: -patients with monolateral, significant, soft carotid stenosis exclusion criteria: * patients with controlateral carotid occlusion * patients with critic stenosis of the external carotid

Keywords: stenting carotid plaque stenosis angioplasty
c-mac videolaryngoscope for insertion of a transesophageal echocardiography probe in icu patients

Conditions: Critical Illness

Summary: transesophageal echocardiography (tee) is commonly used in operating room (cardiac surgery), as well as in other critical care settings. a recent meta-analysis including only three randomized studies demonstrated that the use of a videolaryngoscope for transesophageal echocardiography probe insertion in anesthetized patients undergoing open cardiac surgery was associated with a significant reduction in the number of attempts. insertion and complications rate, compared with blind insertion or a laryngoscope-assisted insertion. icu patients are usually intubated, with multiple complications, requiring high doses of catecholamines, and with frequent coagulation disorders. many of these patients, during their stay in the icu, require a transesophageal echocardiogram. on multiple occasions, due to the critical situation of the patients, due to edema, and coagulation alteration, the placement of the echocardiography probe can be difficult, leading to complications, such as gastric bleeding or lesions in the oropharyngeal mucosa. to avoid complications during the insertion of the tee tube, the investigators consider it necessary to introduce it in the fewest possible attempts. the primary aim of the present study was to compare the success rate of tee probe insertion at the first attempt betweenn the c-mac videolaryngoscope assisted insertion and the blind insertion technique. the secondary aim was to compared differences between the 2 groups in the incidence of complications ( oropharyngeal mucosal injury, hematoma, ....), overall success rate, the number of insertion attempts, and the duration of insertions.

one hundred intubated icu adult patients that require transesophageal echocardiography insertion, will be randomized by means of a computer-generated randomization order into two groups: conventional group (group blind), and videolaryngoscope group (group c-mac). success rate of the selected technique (first attempt), overall success rate, number of attempts, complications, and duration of insertion for technique will be noted.

Eligibility criteria:
inclusion criteria: * icu intubated patients that require transesophageal echocardiography probe insertion exclusion criteria: * patients younger than 18 years and older than 85 years * oropharengeal infection * esophageal injury and anatomic abnormalities * consent refusal for participating in the trial.

Keywords: transesophageal echocardiography videolaryngoscope;